Shahin Gharakhanian MD Consulting LLC, 2022 Mid-Year Report:
July 20, 2022
Selected Projects listed in alphabetical order:
[ACTICOR-BIOTECH, Paris, France]
- US Medical Executive for Acticor Biotech
- Developing Glenzocimab, a humanized monoclonal antibody fragment directed against platelets glycoprotein VI (GPVI). Primary Indication = Stroke.
- ACTISAVE phase II/III Study [(NCT05070260] ongoing.
- Please refer to : www.acticor-biotech.com
[DECOY Therapeutics, Cambridge MA, USA]
- Chair SAB: Scientific Advisory Board
- Developing a <Broad based Antiviral Platform>.
- Please refer to:
- jnjinnovation.com › JLABSNavigator › company
[DEINOVE, Montpellier, France]
- Executive Medical Consultant.
- Phase II: Canada-US clinical trial assessing DNV3837: a novel GI tract-targeted parenteral treatment for Clostridioides difficile infections.
- Please refer to : www.deinove.com
[ENTERA HEALTH, Ankeny, IA, USA]
- Scientific Advisor.
- Clinical Trial for mild to moderate Covid-19 Infection.